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Abstract
Introduction Cough is a common symptom for which
patients seek medical care and is defined as chronic if it has
lasted for more than 8 weeks. The Hull Airway Reflux
Questionnaire (HARQ) was developed with the aim of
eliciting the major component of chronic cough. It com-
prises 14 items with a maximum total score of 70.
A Swedish version (HARQ-S) has previously been devel-
oped but not yet formally validated. The aim of the present
study was to validate the HARQ-S in terms of instrumental
reliability and concurrent validity.
Methods A total of 67 consecutively selected non-smoking
patients with chronic cough and 91 non-smoking allegedly
healthy controls were asked to answer two questionnaires,
the HARQ-S and a local questionnaire, at two occasions
about 3 weeks apart.
Results The HARQ-S showed good psychometric proper-
ties. The patients had significantly higher total scores
(p\ 0.001) compared to the controls, and the question-
naire showed outstanding discrimination ability to distin-
guish between patients and controls, with an area under the
receiver operating characteristic curve of 0.99. Fifty
patients and 77 controls completed the HARQ-S twice,
showing good test–retest agreement in all items as well as
in the total scores in both groups, and without any signif-
icant differences over time.
Conclusion The Swedish version of the HARQ is a valid
and reliable questionnaire with good agreement between
the two measurements in both patients and controls. The
HARQ-S has good reliability and validity and can be used
as a diagnostic tool in Swedish-speaking patients with
chronic cough.
Keywords Chronic cough  Cough hypersensitivity 
Questionnaire
Introduction
Cough is a common symptom in patients with different
pulmonary diseases and is defined as chronic when it has
lasted for more than 8 weeks [1]. Common causes of
chronic cough are asthma, chronic obstructive pulmonary
disease, gastro-oesophageal reflux disease, and cancer. In
many patients, the cause of the chronic cough remains
unclear and is refractory to treatment [2, 3]. In a specialist
clinic as many as 42 % of patients with cough could be
labelled as suffering from chronic cough without any
medical explanation, also known as chronic idiopathic
cough [2].
The Hull Airway Reflux Questionnaire (HARQ) was
developed in the UK, from the Reflux Symptom Index [4],
with the aim of eliciting the major components of chronic
cough. The English version of the HARQ is validated and
has good psychometric properties, internal consistency, and
test–retest repeatability. It has a high sensitivity and
specificity with a very striking receiver operating charac-
teristic (ROC) curve, and is responsive to treatment [5].
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In a pilot study, the HARQ was translated from English
to Swedish [6]. In concordance with the English version,
the Swedish version (HARQ-S) showed that patients with
chronic cough had significantly higher total scores com-
pared to healthy controls, and the ROC curve showed
outstanding discrimination ability to distinguish patients
with chronic cough from healthy controls [6]. It has also
been shown to be responsive to treatment after oral intake
of natural capsaicin in patients with chronic cough [7]. The
preliminary Swedish version has not yet been formally
validated, and there is a need to further assess instrumental
reliability of the questionnaire.
The aim of the present study was to validate the HARQ-
S in terms of instrumental reliability (degree of agreement,




The HARQ-S questionnaire and a local questionnaire were
answered at two occasions about 3 weeks apart [6, 8]. At
the first opportunity, both questionnaires were handed out
in person, and at the second occasion, the questionnaires
were sent by postal mail, with a prepaid return envelope.
The participants were asked to answer the questions based
on their condition as experienced during the previous
month. The participants were reminded once within
2 weeks, by telephone, for complementary answers.
Written informed consent was obtained from all par-
ticipants after they had received information about the
study, both verbally and in writing. The study was
approved by the Regional Ethical Review Board of
Gothenburg, Sweden (number: 542-14).
Patients
The patients were consecutively selected from May 2011 to
June 2012 and from February 2014 to May 2015, when
they attended the Department of Asthma and Allergology
at the Sahlgrenska University Hospital in Gothenburg,
Sweden. All patients had been referred to the clinic due to
having had at least 8 weeks of coughing, defined as chronic
cough.
Control Group
The healthy controls, selected to be similar to the patients
in age and sex distribution, were recruited over a period of
about 9 months. They were subjectively healthy and were
recruited among friends and staff at the Sahlgrenska
University Hospital. They were screened using questions
on cough and airway symptoms. Anyone identified as




The local questionnaire contained questions regarding
demographic data (age, gender, and smoking habits), air-
way symptoms [8], and any change in health status during
the past month.
The HARQ-S
The HARQ-S is a self-administered questionnaire and
consists of 14 items (Table 1). The participants were asked
to evaluate how different problems had affected them
during the previous month, on a scale of 0–5 (0 = no
problem; 5 = severe/frequent problems). The total score of
the questionnaire varies from 0 to 70 points. A total score
of\13 points is regarded as normal [5].
Statistical Methods
Descriptive statistics were used to examine the data. Data
are presented for continuous variables as mean and stan-
dard deviation (SD), mean and 95 % confidence interval
(CI), and median and range. Categorical variables are
presented in percentage (%) and numbers.
For comparison between groups (patients vs. controls,
and males vs. females), Mann–Whitney U-test and
unpaired t test were used for continuous variables. For
calculation of male/female ratio, Fisher’s exact test was
used.
To check the suitability of the HARQ-S, the percentages
of participants obtaining the lowest possible score of 0
(floor effect) and highest possible score of 5 (ceiling effect)
for each item were calculated at the first occasion.
Instrumental Reliability
For comparison over time, the Wilcoxon signed-rank test
was used for continuous variables, and sign test was used
for categorical variables.
For each individual item, test–retest reliability between
occasion 1 and occasion 2 is presented as a percentage (%)
of decrease/equal/increase degree of agreement [9]. Test–
retest reliability for individual question items was also
measured using the weighted kappa statistics [10]. The
repeatability of the total score was estimated using the
method described by Bland and Altman, including
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calculation of limits of agreement equal to the mean dif-
ference of the test–retest values ± twice the SD [11].
Moreover, test–retest reliability for the total score was
measured using intraclass correlation coefficient (ICC)
[12], and the SD of each participant’s response in total
score was calculated using intraindividual standard devia-
tion (IISD) [13].
Internal consistency reliability was expressed as Cron-
bach’s coefficient alpha (a). A coefficient of [0.70 is
considered to be acceptable and satisfactory reliability
[14].
Concurrent Validity
The ability of the questionnaire to distinguish patients from
control subjects was evaluated by constructing a ROC
curve [15]. An area under the curve of more than 0.90
indicates that a method has outstanding discrimination
ability to distinguish two groups from each other [16].
All tests were two-tailed, and the results were consid-
ered significant if p\ 0.05.
The statistical analyses were carried out using SAS
Version 9.3 (SAS Institute, Inc., Cary, NC, USA) and IBM
SPSS Version 22 (IMB SPSS. Inc., New York, USA).
Results
Participants
The patient group consisted of 67 non-smoking patients (7
men) with a mean age of 50.1 years (SD = 13.8), and the
control group of 91 non-smoking, subjectively healthy
individuals (18 men), with a mean age of 47.6 years
(SD = 13.1). There were no significant differences
between the two groups regarding age (data not shown),
and no significant difference was found in male/female
ratios between the two groups (data not shown).
The HARQ-S
The median total score of the HARQ-S from the first
question occasion was 31.0 (range: 0–65) in the patient
group, and 1.0 (range: 0–18) among the controls
(p\ 0.001). The cut-off limit of 13 points was exceeded in
63 patients (94 %; 57 women), and in one female control
subject. Among the patients, the median total score for
women was 31.0 (range: 2–65) and 31.0 (range: 4–37) for
men (NS). The female patients had significantly higher
scores for ‘‘cough brought out by singing or speaking’’
(p\ 0.05) compared to men; otherwise, there were no
gender differences. For the female control subjects, the
median total score was 1.0 (range: 0–18), and 0 (range:
0–6) (NS) for the men. The female controls had signifi-
cantly higher scores for ‘‘clearing your throat’’ compared to
men (p\ 0.05), but no other gender differences were
found in the control group.
Psychometric Properties
The distribution of the HARQ-S was considered to be
normal in the patient group. The prevalence of patients
with the lowest possible score of 0 (floor effect) was
between 4.5 and 57 %, with the lowest prevalence for
Table 1 Items of the Hull Airway Reflux Questionnaire
Within the last month, how did the following problems affect you? (0 = no problem and 5 = severe/frequent problem)
Hoarseness or a problem with your voice 0 1 2 3 4 5
Clearing your throat 0 1 2 3 4 5
Excess mucus in the throat, or drip down the back of your nose 0 1 2 3 4 5
Retching or vomiting when you cough 0 1 2 3 4 5
Cough on first lying down or bending over 0 1 2 3 4 5
Chest tightness or wheeze when coughing 0 1 2 3 4 5
Heartburn, indigestion, stomach acid coming up (or do you take medications for this, if yes score 5) 0 1 2 3 4 5
A tickle in your throat, or a lump in your throat 0 1 2 3 4 5
Cough with eating (during or soon after meals) 0 1 2 3 4 5
Cough with certain foods 0 1 2 3 4 5
Cough when you get out of bed in the morning 0 1 2 3 4 5
Cough brought on by singing or speaking (for example, on the telephone) 0 1 2 3 4 5
Coughing during the day rather than night 0 1 2 3 4 5
A strange taste in your mouth 0 1 2 3 4 5
Total score 70 – – – – –
This is self-administered and has 14 items. Responses to each question can vary from 0 to 5
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‘‘clearing your throat’’ and the highest for ‘‘a strange taste
in your mouth’’. The prevalence of patients with the
highest possible score of 5 (ceiling effect) was between 7.5
and 30 %, with the lowest prevalence for ‘‘chest tightness
and wheeze’’ and the highest for ‘‘coughing during the day
rather than night’’. The distribution of the control popula-
tion was highly skewed; 42 out of 91 (46 %) had a total
score of 0. The prevalence of controls with the lowest
possible score of 0 (floor effect) was between 68 and 99 %,
with the lowest prevalence for ‘‘clearing your throat’’ and
the highest for ‘‘cough with certain food’’. The prevalence
of controls with the highest possible score of 5 (ceiling
effect) was between 1 and 6.6 %, with the lowest preva-
lence for ‘‘coughing during the day rather than night’’ and
the highest for ‘‘heartburn’’.
Instrumental Reliability
Reproducibility was calculated on the subjects who
answered the HARQ-S twice. In total, 50 patients (5 men)
and 77 controls (15 men) answered the questionnaire at two
opportunities. Seventeen patients (16 did not answer, and
one had caught a cold) and 14 control subjects (8 did not
answer, and 6 had caught a cold) did not participate the
second time. The mean duration between the two answer-
ing opportunities was 27.2 (SD = 19.2) days in the patient
group and 22.9 (SD = 15.2) days among the controls (NS).
Results for individual question items from the first and
second occasions, and percentage of agreement between
the two occasions are shown in Table 2. In the patient
group, equal percentages of agreement between the two
occasions ranged from 32 to 70 %, and in the control group
from 75.3 to 100 %. There were no significant differences
in either group between the individual items or in the total
scores between the first and second occasions. Table 3
shows the weighted kappa statistics for each of the 14
items. The lowest weighted kappa value in the patient
group was 0.38 (coughing during the day), and the highest
was 0.73 (heartburn). The lowest value among the healthy
controls was -0.01 (coughing from speaking) and the
highest was 0.91 (heartburn).
Limits of agreement, IISD, and ICC of the total score
are presented in Table 4. The standard deviation of the
differences was 8.12 in the patient group and 2.45 in the
control group, the ICC showed high agreement in both
groups (0.83 and 0.68, respectively), and the IISD was 5.69
in the patient group and 1.72 in the control group.
The Cronbach’s alpha coefficient, representing the
internal consistency reliability, was 0.82 in the patient
group and 0.64 in the control group.
Concurrent Validity
The area under the ROC curve was 0.99, which corre-
sponds to outstanding discrimination ability between
patients and controls (Fig. 1).
Discussion
In most ways, the findings of the HARQ-S are consistent
with those from the original English version. The main
results of the Swedish version can be summarized as fol-
lows. First, the results showed that the HARQ-S has good
psychometric properties. Second, the patients with chronic
cough had significantly higher total scores compared to the
control group, and the area under the ROC curve showed
outstanding discrimination ability to distinguish between
patients with chronic cough and controls. Third, for the
total score, the test–retest agreement was considered to be
good in all items, without any significant differences over
time, and the test–retest reliability was considered to be
good. Further, the HARQ-S had good internal consistency
reliability.
The HARQ-S showed good psychometric properties,
and no single response was given by more than 57 % of the
chronic cough patients, in line with the results from the
original HARQ study [5]. Further, the HARQ-S results in
the present study demonstrated no differences in the total
scores between women and men with chronic cough in
disparity to the original study [5] and to the results from a
former Swedish pilot study [6], both showing significantly
higher total scores for women than men. One possible
reason for not finding any gender differences in the present
study may be the sparse number of male patients included
in comparison to the previous studies [5, 6]. Likewise, we
found no gender differences among the healthy controls.
Test–retest reliability can be evaluated using percentage
of agreement [9] and weighted kappa statistics [10]. In the
original version of the HARQ, test–retest reliability was
studied using weighted kappa statistics in a group of
patients with chronic cough but not among controls [5]. In
this study, we evaluated test–retest reliability in both
groups, and we used both the percentage agreement
statistics and the weighted kappa statistics. The results
showed that the percentages of agreement were satisfactory
in both groups. According to Viera et al., a weighted kappa
value of[0.40 is suggested to show moderate agreement
[10], and in the English-speaking patient group, the
weighted kappa values ranged from 0.40 to 0.79 [5],
whereas the present results ranged from 0.38 to 0.73,
demonstrating almost the same kappa values. In
1000 Lung (2016) 194:997–1005
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Table 2 Results of the HARQ-S at the first and second occasions, and percentage of agreement between these two occasions, in 50 patients with
chronic cough and 77 controls
Patients Change from occasion 1 to
occasion 2












0 14 (28 %) 13 (26 %) 67 (87 %) 69 (89.6 %)
1 9 (18 %) 7 (14 %) 5 (6.5 %) 6 (7.8 %)
2 1 (2 %) 7 (14 %) 4 (5.2 %) 1 (1.3 %)
3 10 (20 %) 8 (16 %) Dec 14 (28 %) 1 (1.3 %) 1 (1.3 %) Dec 4 (5.2 %)
4 5 (10 %) 8 (16 %) Equ 25 (50 %) Equ 72 (93.5 %)
5 11 (22 %) 7 (14 %) Inc 11 (22 %) 0.69 Inc 1 (1.3 %) 0.38
Throat_cl
0 2 (4.1 %) 6 (12.2 %) 53 (68.8 %) 52 (67.5 %)
1 4 (8.2 %) 6 (12.2 %) 17 (22.1 %) 22 (28.6 %)
2 8 (16.3 %) 6 (12.2 %) 7 (9.1 %) 3 (3.9 %)
3 12 (24.5 %) 5 (10.2 %) Dec 16 (32.7 %) Dec 10 (13 %)
4 10 (20.4 %) 12 (24.5 %) Equ 20 (40.8 %) Equ 58 (75.3 %)
5 13 (26.5 %) 14 (28.6 %) Inc 13 (26.5 %) 0.71 Inc 9 (11.7 %) 1.00
Mucus
0 5 (10 %) 8 (16 %) 67 (87 %) 65 (84.4 %)
1 7 (14 %) 2 (4 %) 7 (9.1 %) 10 (13 %)
2 10 (20 %) 9 (18 %) 3 (3.9 %) 2 (2.6 %)
3 9 (18 %) 13 (26 %) Dec 16 (32 %) Dec 4 (5.2 %)
4 11 (22 %) 9 (18 %) Equ 16 (32 %) Equ 67 (87 %)
5 8 (16 %) 9 (18 %) Inc 18 (36 %) 0.86 Inc 6 (7.8 %) 0.75
Retching
0 18 (36 %) 19 (38 %) 75 (97.4 %) 76 (98.7 %)
1 12 (24 %) 15 (30 %) 1 (1.3 %) 1 (1.3 %)
2 4 (8 %) 4 (8 %) 1 (1.3 %) 0 (0 %)
3 7 (14 %) 5 (10 %) Dec 17 (34 %) Dec 2 (2.6 %)
4 4 (8 %) 4 (8 %) Equ 22 (44 %) Equ 75 (97.4 %)
5 5 (10 %) 3 (6 %) Inc 11 (22 %) 0.34 Inc 0 (0 %) 0.50
Lying down
0 15 (30 %) 16 (32 %) 75 (97.4 %) 74 (96.1 %)
1 8 (16 %) 6 (12 %) 2 (2.6 %) 2 (2.6 %)
2 12 (24 %) 10 (20 %) 0 (0 %) 1 (1.3 %)
3 4 (8 %) 8 (16 %) Dec 12 (24 %) Dec 2 (2.6 %)
4 1 (2 %) 3 (6 %) Equ 25 (50 %) Equ 72 (93.5 %)
5 10 (20 %) 7 (14 %) Inc 13 (26 %) 1.00 Inc 3 (3.9 %) 1.00
Wheeze
0 14 (28 %) 17 (34 %) 74 (96.1 %) 77 (100 %)
1 9 (18 %) 10 (20 %) 3 (3.9 %) 0 (0 %)
2 8 (16 %) 5 (10 %)
3 7 (14 %) 8 (16 %) Dec 15 (30 %) Dec 3 (3.9 %)
4 9 (18 %) 4 (8 %) Equ 22 (44 %) Equ 74 (96.1 %)
5 3 (6 %) 6 (12 %) Inc 13 (26 %) 0.85 Inc 0 (0 %) 0.25
Heartburn
0 26 (52 %) 21 (42 %) 63 (81.8 %) 61 (79.2 %)
1 4 (8 %) 4 (8 %) 5 (6.5 %) 7 (9.1 %)
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Table 2 continued
Patients Change from occasion 1 to
occasion 2











2 2 (4 %) 6 (12 %) 2 (2.6 %) 3 (3.9 %)
3 4 (8 %) 2 (4 %) Dec 4 (8 %) 1 (1.3 %) 0 (0 %) Dec 3 (3.9 %)
4 2 (4 %) 2 (4 %) Equ 35 (70 %) 0 (0 %) 0 (0 %) Equ 70 (90.9 %)
5 12 (24 %) 15 (30 %) Inc 11 (22 %) 0.12 6 (7.8 %) 6 (7.8 %) Inc 4 (5.2 %) 1.00
Tickle
0 5 (10 %) 12 (24 %) 68 (88.3 %) 74 (96.1 %)
1 11 (22 %) 5 (10 %) 7 (9.1 %) 1 (1.3 %)
2 6 (12 %) 7 (14 %) 1 (1.3 %) 1 (1.3 %)
3 6 (12 %) 6 (12 %) Dec 16 (32 %) 1 (1.3 %) 1 (1.3 %) Dec 6 (7.8 %)
4 9 (18 %) 9 (18 %) Equ 23 (46 %) Equ 69 (89.6 %)
5 13 (26 %) 11 (22 %) Inc 11 (22 %) 0.44 Inc 2 (2.6 %) 0.29
Eating
0 19 (38 %) 17 (34 %) 77 (100 %) 77 (100 %)
1 6 (12 %) 4 (8 %)
2 5 (10 %) 4 (8 %)
3 5 (10 %) 7 (14 %) Dec 10 (20 %) Dec 0 (0 %)
4 8 (16 %) 9 (18 %) Equ 24 (48 %) Equ 77 (100 %)
5 7 (14 %) 9 (18 %) Inc 16 (32 %) 0.33 Inc 0 (0 %)
Certain_foods
0 17 (34 %) 17 (34 %) 75 (97.4 %) 75 (97.4 %)
1 7 (14 %) 6 (12 %) 1 (1.3 %) 1 (1.3 %)
2 4 (8 %) 4 (8 %) 1 (1.3 %) 1 (1.3 %)
3 6 (12 %) 8 (16 %) Dec 11 (22 %) Dec 2 (2.6 %)
4 8 (16 %) 9 (18 %) Equ 27 (54 %) Equ 74 (96.1 %)
5 8 (16 %) 6 (12 %) Inc 12 (24 %) 1.00 Inc 1 (1.3 %) 1.00
Out_of_bed
0 15 (30 %) 12 (24 %) 73 (94.8 %) 72 (93.5 %)
1 7 (14 %) 7 (14 %) 2 (2.6 %) 3 (3.9 %)
2 5 (10 %) 9 (18 %) 2 (2.6 %) 1 (1.3 %)
3 9 (18 %) 9 (18 %) Dec 9 (18 %) 0 (0.0 %) 1 (1.3 %) Dec 2 (2.6 %)
4 9 (18 %) 8 (16 %) Equ 26 (52 %) Equ 73 (94.8 %)
5 5 (10 %) 5 (10 %) Inc 15 (30 %) 0.31 Inc 2 (2.6 %) 1.00
Speaking
0 10 (20.0 %) 9 (18.0 %) 76 (98.7 %) 75 (97.4 %)
1 2 (4.0 %) 4 (8.0 %) 1 (1.3 %) 0 (0.0 %)
2 11 (22.0 %) 8 (16.0 %) 0 (0.0 %) 0 (0.0 %)
3 8 (16.0 %) 9 (18.0 %) Dec 11 (22.0 %) 0 (0.0 %) 2 (2.6 %) Dec 1 (1.3 %)
4 10 (20.0 %) 11 (22.0 %) Equ 26 (52.0 %) Equ 74 (96.1 %)
5 9 (18.0 %) 9 (18.0 %) Inc 13 (26.0 %) 0.84 Inc 2 (2.6 %) 1.00
Day
0 5 (10 %) 6 (12 %) 75 (97.4 %) 73 (94.8 %)
1 3 (6 %) 5 (10 %) 1 (1.3 %) 1 (1.3 %)
2 6 (12 %) 3 (6 %) 1 (1.3 %) 1 (1.3 %)
3 10 (20 %) 7 (14 %) Dec 15 (30 %) 0 (0 %) 1 (1.3 %) Dec 1 (1.3 %)
4 12 (24 %) 11 (22 %) Equ 19 (38 %) 0 (0 %) 0 (0 %) Equ 72 (93.5 %)
5 14 (28 %) 18 (36 %) Inc 16 (32 %) 1.00 0 (0 %) 1 (1.3 %) Inc 4 (5.2 %) 0.38
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accordance with Morice et al., we found that among the
patients, the item ‘‘cough during the day rather than the
night’’ had the lowest kappa value (0.40 and 0.38,
respectively) [5]; otherwise, all kappa values were above
0.40. Among the controls, the present weighted kappa
results were in some items close to or below zero (cough
related to lying down, wheeze, eating, and speaking), but
on the other hand, these items had a high percentage of
equal agreement, with values above 93 %. The findings of
low weighted kappa values in combination with a high
percentage of agreement, are paradox, but can be explained
by the fact that it is impossible to calculate kappa if the
percentages of agreement are close to 0 % or close to
100 % [17, 18].
The standard deviation of the differences showed almost
the same results in the present study as in the original study
(8.12 and 8.23, respectively) [5]. Further, the ICC was used
for analysing test–retest reliability. An ICC value[0.4 is
generally regarded as a moderate correlation and[0.75 as
a strong correlation [12]. The ICC of the HARQ-S was
considered to be good, with high values in both patients
and controls (0.83 and 0.68, respectively). The IISD,
Table 2 continued
Patients Change from occasion 1 to
occasion 2












0 29 (58 %) 27 (54 %) 73 (94.8 %) 75 (97.4 %)
1 6 (12 %) 7 (14 %) 2 (2.6 %) 2 (2.6 %)
2 8 (16 %) 3 (6 %) 1 (1.3 %) 0 (0 %)
3 2 (4 %) 8 (16 %) Dec 8 (16 %) 0 (0 %) 0 (0 %) Dec 4 (5.2 %)
4 1 (2 %) 2 (4 %) Equ 30 (60 %) 1 (1.3 %) 0 (0 %) Equ 72 (93.5 %)
5 4 (8 %) 3 (6 %) Inc 12 (24 %) 0.50 0 (0 %) 0 (0 %) Inc 1 (1.3 %) 0.38
Total score 31.6 (13.0) 31.7 (14.3) 0.08 (8.1) 1.9 (2.6) 1.8 (3.5) -0.08 (2.4)
30.0 (4.0–64.0) 33.0 (4.0–59.0) -0.5 (-20.0–19.8) 1.00 (0.0–11.0) 0.0 (0.0–20.0) -0.0 (-5.0–14.0)
n = 50 n = 50 n = 50 0.96 n = 77 n = 77 n = 77 0.17
For categorical variables, n (%) is presented. For continuous variables mean (SD)/median (range)/n = is presented. For comparison over time,
the Wilcoxon signed-rank test was used for continuous variables and sign test was used for categorical variables
Dec decrease, Equ equal, Inc increase, n number, SD standard deviation
Table 3 Weighted kappa
statistics (95 % CI) for each
item, in patients with chronic
cough and controls
Item wkappa (patients n = 50) wkappa (controls n = 77)
Hoarseness 0.60 (0.46–0.74) 0.72 (0.47–0.96)
Throat_clearing 0.43 (0.25–0.62) 0.51 (0.34–0.68)
Mucus 0.45 (0.30–0.59) 0.54 (0.25–0.82)
Retching 0.53 (0.37–0.70) 0.49 (0.15–0.84)
Lying_down 0.57 (0.41–0.73) -0.03 (-0.05–0.00)
Wheeze 0.51 (0.34–0.67) -0.00 (-0.00–-0.00)
Heartburn 0.73 (0.60–0.86) 0.91 (0.83–0.98)
Tickle 0.54 (0.38–0.70) 0.30 (0.06–0.54)
Eating 0.60 (0.45–0.74) (–)
Certain_foods 0.59 (0.43–0.76) 0.32 (-0.09–0.73)
Out_of_bed 0.65 (0.53–0.78) 0.55 (0.16–0.94)
Speaking 0.64 (0.51–0.78) -0.01 (-0.02–0.01)
Day 0.38 (0.20–0.56) 0.27 (-0.15–0.69)
Taste 0.64 (0.49–0.80) 0.18 (-0.14–0.50)
CI confidence interval, n number, (–) in both occasions no occasions of ‘‘eating’’ was found, and weighted
kappa could not be calculated
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describing the within-person variation, was likewise good
in both groups, though somewhat lower among the control
subjects.
The internal consistency reliability, expressed as Cron-
bach’s coefficient a, reflecting the HARQ’s ability to
indicate the extent to which items are related, was high in
the patient group (0.82) but lower in the control group
(0.64). This is in line with the study by Morice et al.
showing a Cronbach’s a coefficient of 0.81 in patients with
chronic cough [5].
In accordance with other studies by Morice et al. [5] and
Ternesten-Hasse´us et al. [6], the ROC curve in the present
study showed outstanding discrimination ability to distin-
guish patients with chronic cough from healthy controls.
Cough is a worldwide major medical problem, being the
cardinal symptom not only of many severe diseases but
also of different, quite harmless conditions. Diagnosing
cough requires a battery of examinations, and this ques-
tionnaire could be a useful tool in discriminating among
different kinds of cough. Morice et al. postulated that a
majority of patients with chronic cough represent a discrete
clinical entity, the newly established ‘‘Cough hypersensi-
tivity syndrome’’ [19, 20]. Within the syndrome, there are
different phenotypes, but it has been suggested that a
majority of the patients suffer from a precipitant of non-
acid reflux, with gaseous mist which causes inflammation
and gives rise to hypersensitivity and coughing [19, 20]. In
accordance with this, we suggest entitle the questionnaire
‘‘The Hull Cough Hypersensitivity Questionnaire’’.
Conclusions
In conclusion, the present results conform well to the
original questionnaire by Morice et al. [5], and we found in
the present study a good agreement between the two
measurements in both patients and controls. The HARQ-S
has good reliability and validity and can be used as a
diagnostic tool in Swedish-speaking patients with chronic
cough.
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Total score (patients) (n = 50) 0.076 (-15.847; 15.999) (8.124) -0.500
(-20.000–19.800)
0.9584 0.83 (0.71; 0.90) 5.69
Total score (controls) (n = 77) -0.078 (-4.887; 4.731) (2.454) 0.000
(-5.000–14.000)
0.1736 0.68 (0.54; 0.79) 1.72
Wilcoxon signed-rank test is used to test the difference. For difference mean (95 % CI, limits of agreement)/(SD)/median (range)/n = is
presented
CI Confidence interval, ICC intraclass correlation, IISD intraindividual standard deviation, n number, SD standard deviation
Fig. 1 ROC curve for the ability to distinguish patients with chronic
cough from control subjects
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